NCT00096291View on ClinicalTrials.gov

Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 29, 2000

Primary Completion Date

March 31, 2005

Conditions
Breast Cancer
Interventions
OTHER

Doxorubicin followed by Paclitaxel

"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel Paclitaxel followed by Doxorubicin"

OTHER

Paclitaxel followed by Doxorubicin

"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"

Trial Locations (2)

02114-2617

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Massachusetts General Hospital

OTHER

NCT00096291 - Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer | Biotech Hunter | Biotech Hunter